Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/10584
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGrossmann, Mathisen
dc.contributor.authorPremaratne, Eroshaen
dc.contributor.authorDesai, Jayeshen
dc.contributor.authorDavis, Ian Den
dc.date.accessioned2015-05-16T00:05:23Z
dc.date.available2015-05-16T00:05:23Z
dc.date.issued2008-04-03en
dc.identifier.citationClinical Endocrinology 2008; 69(4): 669-72en
dc.identifier.govdoc18394019en
dc.identifier.otherPUBMEDen
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/10584en
dc.description.abstractSunitinib malate is an oral tyrosine kinase inhibitor used in the treatment of renal cell carcinoma (RCC) and gastrointestinal stromal tumours. Hypothyroidism has been observed in patients treated with sunitinib, but the mechanism whereby sunitinib induces hypothyroidism is unknown.To describe a series of six patients who developed thyrotoxicosis while on sunitinib for metastatic RCC.The study was conducted at Austin Health, a tertiary teaching hospital in Melbourne, Australia.Two patients developed severe thyrotoxicosis within 10 weeks after commencing sunitinib. In contrast, in the four patients who presented with later onset (16-30 weeks) thyrotoxicosis, the thyrotoxicosis was relatively mild, self-limiting and rapidly progressed to hypothyroidism. These patients experienced recurrent episodes of thyrotoxicosis in temporal relation to their cyclical sunitinib treatment. One patient had cytological evidence of lymphocytic thyroiditis.These findings suggest that sunitinib-induced hypothyroidism may be a consequence of preceding thyroiditis with associated transient thyrotoxicosis. As predictive factors are currently unknown, we suggest regular monitoring of thyroid function in all patients commenced on sunitinib. Clinicians treating patients with sunitinib or other similar kinase inhibitors should to be alerted to thyroid dysfunction as a potential toxicity of these agents.en
dc.language.isoenen
dc.subject.otherAdulten
dc.subject.otherAntineoplastic Agents.adverse effects.therapeutic useen
dc.subject.otherCarcinoma, Renal Cell.blood.drug therapyen
dc.subject.otherFemaleen
dc.subject.otherHumansen
dc.subject.otherIndoles.adverse effects.therapeutic useen
dc.subject.otherKidney Neoplasms.blood.drug therapyen
dc.subject.otherMaleen
dc.subject.otherMiddle Ageden
dc.subject.otherPyrroles.adverse effects.therapeutic useen
dc.subject.otherThyrotoxicosis.blood.chemically induced.diagnosisen
dc.subject.otherThyrotropin.blooden
dc.subject.otherThyroxine.blooden
dc.titleThyrotoxicosis during sunitinib treatment for renal cell carcinoma.en
dc.typeJournal Articleen
dc.identifier.journaltitleClinical Endocrinologyen
dc.identifier.affiliationEndocrine Unit, Austin Health, Victoria, Australiaen
dc.identifier.doi10.1111/j.1365-2265.2008.03253.xen
dc.description.pages669-72en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/18394019en
dc.type.austinJournal Articleen
item.languageiso639-1en-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
item.cerifentitytypePublications-
item.grantfulltextnone-
crisitem.author.deptEndocrinology-
crisitem.author.deptEndocrinology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

6
checked on Feb 2, 2023

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.